Under the agreement, scientists at AstraZeneca R&D will access Eidogen-Sertanty’s target informatics platform (TIP) and EVE comparative visualization software to assist drug discovery efforts within their cancer and anti-infective therapeutic programs. The financial terms of the deal were not disclosed.
TIP is a protein structure informatics system that integrates protein structural data and ligand binding site analysis.
“We are very excited that AstraZeneca R&D Boston has selected TIP to assist their drug discovery efforts,” said Dr Steve Muskal, CEO of Eidogen-Sertanty. “We’re confident that TIP will help AstraZeneca scientists accelerate lead discovery programs across a wide variety of target families and therapeutic areas.”
Anglo-Swedish company AstraZeneca is engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services.